Tag: wet AMD
-

J&J Agrees to Buy Ollin Biosciences for $2.2 Billion Upfront, Adding OLN324
Johnson & Johnson agreed to acquire Ollin Biosciences for $2.2 billion upfront. The deal would add OLN324, a Phase 3 candidate for wet AMD and diabetic macular edema. Early results against Vabysmo highlight differences in retinal imaging and leave open whether OLN324 can preserve vision with fewer injections.
-

Kodiak Phase 3: Zenkuda Shows 24-Week Durability in Wet AMD
Kodiak’s Phase 3 DAYBREAK trial met its primary endpoint for both Zenkuda and KSI-501 in wet AMD. Zenkuda stood out as 54% of patients reached 24-week dosing, while KSI-501 met noninferiority without yet establishing a clear added benefit from IL-6 inhibition.